Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study-Reference-Cited by-同舟云学术

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

Author:

Dréno B.,Ribas A.,Larkin J.,Ascierto P.A.,Hauschild A.,Thomas L.,Grob J.-J.,Koralek D.O.,Rooney I.,Hsu J.J.,McKenna E.F.,McArthur G.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

Reference16 articles.

1. ZELBORAF (vemurafenib) Tablets, for Oral Use. South San Francisco, CA: Genentech USA, Inc. 2015.

2. COTELLIC (cobimetinib) Tablets, for Oral Use. South San Francisco, CA: Genentech USA, Inc. 2015.

3. Cotellic 20mg Film-coated Tablets. Welwyn Garden City, UK: Roche Registration Limited 2016.

4. Zelboraf 240mg Film-coated Tablets. Welwyn Garden City, UK: Roche Registration Limited 2016.

5. Mekinist 0.5mg Film-coated Tablets. Research Triangle Park, NC: GlaxoSmithKline 2015.

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocular complications in patients undergoing initial chemotherapy;Gazzetta Medica Italiana Archivio per le Scienze Mediche;2024-09

4. Alternative Synthesis of Cobimetinib;Pharmaceutical Chemistry Journal;2024-04